Sivelestat in subjects with acute lung injury
Acute Lung Injury · ARDS
Enrolment: 600 · Results not recorded
Loading the evidence…
Biologic · ChEMBL NOT QUERIED for recombinant IL-17A: administered recombinant cytokine, no ChEMBL drug entity; resolved=false by entity class, not by a negative search. CTgov 'recombinant interleukin-17A' returned 1 hit, NCT03331835 brodalumab vs fumaric acid esters, REJECTED as a false positive because brodalumab BLOCKS the IL-17 receptor, the opposite of administering IL-17A. No human trial administers recombinant IL-17A. The recorded trials are CLASS-LEVEL analogues for the NEUTROPHIL ELASTASE INHIBITOR comparator arm only (sivelestat, alvelestat, POL6014), all in lung injury, sepsis or CF, none trauma-specific.
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Acute Lung Injury · ARDS
Enrolment: 600 · Results not recorded
Cardiac Disease
Enrolment: 382 · Results not recorded
Septic Shock · Coagulopathy
Enrolment: 120 · Results not recorded
Alpha 1-Antitrypsin Deficiency · COPD
Enrolment: 99 · Results not recorded
Cystic Fibrosis
Enrolment: 32 · Results not recorded
Acute Respiratory Distress Syndrome
Enrolment: 100 · Results not recorded
Aortic Dissection · SIRS
Enrolment: 500 · Results not recorded
Acute Ischemic Stroke
Enrolment: 20 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Acute cutaneous (skin) wound in wild-type and IL-17A-knockout mice
IL-17A deficiency accelerated wound closure with greater myofibroblast differentiation and collagen deposition and fewer neutrophils, whereas administration of recombinant IL-17A delayed closure, lowered collagen deposition and increased neutrophil accumulation. Treating IL-17A-administered mice wi…
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.